NEW YORK (GenomeWeb) – Although Myriad Genetics' forecasted revenues for fiscal year 2017 fell short of Wall Street's expectations, the company yesterday outlined its plan for diversifying its product portfolio and achieving long-term growth.

The company reported FY2016 revenues of $753.8 million, a 4 percent increase from the prior year, and said it is expecting revenues of between $740 million to $760 million in FY2017. Analysts were expecting $755.5 million in revenues for FY2016 and had modeled $788.9 million for the coming 12 months.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

This webinar will walk through key considerations and helpful guidelines to accelerate next-generation sequencing (NGS)-based clinical genomics assay validation for less money and greater confidence in results.

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep.